Horizon Research Group — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$45,125	12
2024	Research	$65,610	20
2023	Research	$30,154	29
2022	Research	$46,164	7
2021	Research	$270,703	24
2020	Research	$18,708	18
2019	Research	$68,127	42

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $208,291 20 payments
Becton, Dickinson and Company $152,000 3 payments
Merck Sharp & Dohme Corporation $90,077 7 payments
Alnylam Pharmaceuticals Inc. $42,741 19 payments
Novo Nordisk AS $40,081 101 payments
AstraZeneca Pharmaceuticals LP $10,950 1 payment
AbbVie, Inc. $450 1 payment

Studies the money was for Research payments · program years 2019–2025

VerHome $152,000 3 payments
A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Participants with End Stage Renal Disease Receiving Hemodialysis. $90,077 7 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $59,609 4 payments
A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $53,183 2 payments
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $45,348 9 payments
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $42,741 19 payments
Nn9535-4321 $40,081 101 payments
A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging in Patients With Chronic Heart Failure With Preserved Ejection Fraction $35,736 1 payment
Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $13,415 3 payments
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia $10,950 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.